13F-HR filed by Finepoint Capital LP
Finepoint Capital LP filed this 13F-HR for the quarter ended 2024-09-30, filed 2024-11-13, with 26 holding rows worth $1,376,031,768.
- Accession
- 0000904454-24-000600
- Filer
- CIK 1608126
- Filed
- 2024-11-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2024
A holdings report, 26 entries on the cover page, a total value of $1,376,031,768 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,376,031,768 with VALUE read as dollars as filed, 13F file number 028-16580. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| QXO INC COM NEW | 82846H405 | Stock | 25,750,781 | $406,089,816 | dollars as filed | |
| SPY | 78462F103 | SHS | 555,000 | $318,436,800 | dollars as filed | put |
| iShares Russell 2000 ETF | 464287655 | SHS | 1,065,000 | $235,247,850 | dollars as filed | put |
| LIBERTY BROADBAND CORP | 530307305 | COM SER C | 1,994,510 | $154,155,678 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 731,960 | $33,194,386 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 54,428 | $29,504,330 | dollars as filed | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 190,072 | $28,379,650 | dollars as filed | |
| TRAVERE THERAPEUTICS INC | 89422G107 | COM | 1,782,267 | $24,933,915 | dollars as filed | |
| SPRINGWORKS THERAPEUTICS INC | 85205L107 | COM | 650,852 | $20,853,298 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 388,835 | $19,605,061 | dollars as filed | |
| SAREPTA THERAPEUTICS INC | 803607100 | COM | 133,535 | $16,677,186 | dollars as filed | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 557,762 | $16,057,968 | dollars as filed | |
| ARVINAS INC | 04335A105 | COM | 574,378 | $14,146,930 | dollars as filed | |
| ACADIA PHARMACEUTICALS INC | 004225108 | COM | 905,384 | $13,924,806 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 256,449 | $13,540,507 | dollars as filed | |
| RELAY THERAPEUTICS INC COM | 75943R102 | Stock | 1,626,146 | $11,513,114 | dollars as filed | |
| PROTHENA CORP PLC SHS | G72800108 | Stock | 433,471 | $7,251,970 | dollars as filed | |
| SOLID BIOSCIENCES INC | 83422E204 | COMMON STOCK | 961,251 | $6,699,919 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 707,404 | $5,652,158 | dollars as filed | |
| SWIFTMERGE ACQUISITION CORP | G63836111 | *W EXP 12/13/202 | 490,000 | $39,200 | dollars as filed | |
| COMPASS DIGITAL ACQUISITION CO | g2476c123 | WT | 459,906 | $28,054 | dollars as filed | |
| MONEYHERO LIMITED | G6202B119 | *W EXP 09/13/202 | 895,000 | $26,850 | dollars as filed | |
| MARBLEGATE ACQUISITION CORP | 56608A113 | *W EXP 08/31/202 | 735,000 | $25,284 | dollars as filed | |
| SUMMIT HEALTHCARE ACQUISITION | g9845f117 | WT | 489,999 | $24,206 | dollars as filed | |
| CALIDI BIOTHERAPEUTICS INC | 320703309 | COM NEW | 12,500 | $14,249 | dollars as filed | |
| CALIDI BIOTHERAPEUTICS INC | 320703119 | *W EXP 03/14/202 | 655,200 | $8,583 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000904454-24-000600 | this filing | 2024-11-13 | acceptance time not in the bulk data set |